ArticleFrontiers in pharmacology2024
Epidemiology of respiratory syncytial virus in hospitalized children over a 9-year period and preventive strategy impact.
Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Observational
- Review
- Impact of Nirsevimab on Pediatric RSV-Related Lower Respiratory Tract Infections: A Retrospective Pre-Post Observational Study in Tuscany, Italy.Infectious diseases and therapy · 2026Article
- Article
- IFN-λ4 Exhibits Differential Induction and Antiviral Activity in RSV and HMPV Infections.Viruses · 2026Article
- Risk prediction of pediatric intensive care unit admission in children with respiratory syncytial virus infection using interpretable machine learning.Frontiers in medicine · 2026Article
- Serotype 3 invasive pneumococcal disease in Tuscany across the eras of conjugate vaccines (2005-2024) and anthropic-driven respiratory virus fluctuations.Human vaccines & immunotherapeutics · 2025Article
- Public health impact of nirsevimab and reduction of RSV hospitalisation in all infants: early real-world data from Tuscany (Italy) in the 2024-25 RSV season.European journal of pediatrics · 2025Observational
- Predictive Factors and Clinical Markers of Recurrent Wheezing and Asthma After RSV Infection.Viruses · 2025Review
- Opposite Responses of Interferon and Proinflammatory Cytokines Induced by Human Metapneumovirus and Respiratory Syncytial Virus in Macrophages.Pathogens (Basel, Switzerland) · 2025Article
- Hospitalizations for bronchiolitis among infants before and after the SARS-CoV-2 pandemic: an area-based study of the Emilia-Romagna Region, Italy.Italian journal of pediatrics · 2025Article
- Six-year epidemiological dynamics of human respiratory syncytial virus infections in children in central China (2019-2024): pandemic suppression, 2023 resurgence, and immune debt effect.Frontiers in cellular and infection microbiology · 2025Article
- The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy.Frontiers in public health · 2025Article
- Exploring the epidemiological burden of RSV pre- and post-COVID-19 pandemic: A Jordanian tertiary hospital experience.The Journal of international medical research · 2024Article
- Review
- Interferon Epsilon-Mediated Antiviral Activity Against Human Metapneumovirus and Respiratory Syncytial Virus.Vaccines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.